Sensorion reports promising gene therapy data for congenital deafness. Discover what it means for hearing loss treatment and future clinical breakthroughs.
Roche and BMS present updated prasinezumab and BMS-986446 data at AD/PD 2026. What it means for Phase III plans and tau targeting. Read the analysis.
FDA approval of Restylane Contour for temple hollowing signals a shift in facial aesthetics. Discover what this means for the industry and future treatments.
Can HMPL-760 improve outcomes in relapsed DLBCL? Explore how HUTCHMED is advancing next-gen BTK inhibitors in China.
IDEAYA Biosciences nears darovasertib trial data. Discover how results could reshape metastatic uveal melanoma treatment strategies.
Apogee Therapeutics prepares to release 52-week APEX data for zumilokibart. Discover what it could mean for eczema treatment and competition.
LGM Pharma expands U.S. CDMO capacity with a $15M investment across Texas and Colorado. Explore what this means for domestic drug manufacturing. Read more.
Triana Biomedicines launches TRI-611 trial in ALK lung cancer. Can molecular glue degraders overcome resistance? Read the full analysis.
ADSTILADRIN gains NCCN upgrade in bladder cancer. Discover what this means for gene therapy adoption, clinical use, and future NMIBC treatment trends.
Origin Genomics launches in New York to advance germline gene correction and MRT under IRB oversight. Analyse what it means for US gene editing regulation.